%0 Journal Article
%T Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
%A Se Park
%A Eun Cho
%A Soo-Mee Bang
%A Dong Shin
%A Jae Lee
%A Young Lee
%J BMC Cancer
%D 2005
%I BioMed Central
%R 10.1186/1471-2407-5-21
%X Patients with MBC that had progressed after at least one prior chemotherapy regimen containing anthracyclines received docetaxel 75 mg/m2 followed by cisplatin 60 mg/m2 every 3 weeks for a maximum of 6 cycles or until disease progression.Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for efficacy. The objective response rate was 31% (95% CI, 16¨C45%) with 3 complete responses. The median time to disease progression was 7 months, and the median overall survival was 23 months (median follow-up of 41 months). Neutropenia was the most frequently observed severe hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-hematologic toxicities. No treatment-related death was observed.In conclusion, we found docetaxel plus cisplatin to be an active and safe chemotherapy regimen for patients with MBC resistant to anthracyclines.In the management of breast cancer, anthracycline-based chemotherapy regimens remain standard adjuvant or first-line palliative treatment. Furthermore, some patients cannot be treated with anthracyclines due to impaired cardiac function. It is thus important to identify active, well-tolerated, not anthracycline cross-resistant, salvage regimens [1].Taxanes (docetaxel and paclitaxel) are currently the most extensively studied new chemotherapeutic agents for metastatic breast cancer (MBC). Single-agent docetaxel has demonstrated significant survival advantages over other recognized regimens in 2 large randomized trials in patients with anthracycline-pretreated MBC [2,3]. Phase II data suggest that docetaxel is the most active agent yet available for the treatment of MBC [4]. Docetaxel also has some activity in paclitaxel-resistant MBC [5].Cisplatin monotherapy has shown response rate of 9% in salvage settings, and 50% as first-line therapy [6]. Because docetaxel and cisplatin are both active a
%U http://www.biomedcentral.com/1471-2407/5/21